WebNov 1, 2024 · Phesgo is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see Dosage and Administration (2.2) and Clinical Studies (14.1)]. WebPhesgo contains the active substances pertuzumab and trastuzumab. For more information about the use of Phesgo and the other medicines the patients will receive, see the package leaflet. How is Phesgo used? Phesgo can only be obtained with a prescription and treatment should be started under the supervision
Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) dosing
WebThe combination of trastuzumab and pertuzumab as an injection under your skin is called Phesgo. Having these drugs this way is quicker than having them into your bloodstream. You usually have these every 3 weeks. Your doctor will let you know if this is suitable for you and how many treatments you will have. WebAug 8, 2024 · Phesgo contains a combination of hyaluronidase, pertuzumab, and trastuzumabis. Phesgo is a cancer medicine that is used alone or with other medicines to treat early-stage breast cancer. Phesgo is also used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). sunbeam motorized tie rack
Dual-action benefits: Global (action-inherent) and local (transient ...
WebMar 2, 2024 · Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have … WebPHESGO TM is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic test. Important Safety Information WebMar 25, 2024 · This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer … pallof stretch